Halozyme Reports Second Quarter 2017 Results

Published: Aug 09, 2017

SAN DIEGO, Aug. 8, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the second quarter ended June 30.

"A clear highlight of the second quarter was approval of Genentech's RITUXAN HYCELATM in the U.S., and the resulting strong interest from new potential partners who seek to coformulate with our ENHANZE® technology," said Dr. Helen Torley, president and chief executive officer. "We have strong momentum in the ENHANZE® business with continued growth in royalties and a number of catalysts in the second half of 2017, including Lilly's recent start of their Phase 1 study, Janssen's upcoming start of their Phase 3 study of subcutaneous daratumumab and our expectation for a new collaboration agreement.

Back to news